21 CFR 358.701 - Scope.
prev | next
(a) An over-the-counter dandruff, seborrheic dermatitis, or psoriasis drug product in a form suitable for topical application is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this subpart and each general condition established in § 330.1 of this chapter.
Title 21 published on 2014-04-01.
No entries appear in the Federal Register after this date, for 21 CFR Part 358.